Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | +65.15% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.20 | N/A | +65.15% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions but remains focused on upcoming clinical trials. They did not provide any forward guidance.
Management highlighted ongoing challenges in the market.
They emphasized the importance of upcoming trials for future growth.
There was no specific guidance provided for the next quarter.
Sarepta Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 1.23% likely due to the lack of revenue information and no forward guidance. The market may be cautious as management pointed out challenges ahead, particularly regarding ongoing trials and market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STATE STR CORP
Oct 23, 2017